Affordable precision Target Cynvenio’s focus on affordable, clinically actionable precision medicine to position solutions that reduce cost per actionable mutation and accelerate decision making for cancer patients and trial enrollment.

LiquidBiopsy leverage Highlight opportunities around their proprietary LiquidBiopsy technology for real-time molecular profiling from whole blood, enabling repeatable monitoring programs and post-treatment response assessment for oncology brands and CROs.

ClearID expansion Pitch potential upsell of ClearID tests for broader cancer detection and monitoring in clinics with blood-based testing workflows, emphasizing ease of blood draw and patient-friendly workflows.

SMB-to-midmarket fit Position Cynvenio as a strategic partner for mid-size cancer centers and contract researchers seeking cost-effective genomic testing with actionable targets, differentiating from larger incumbents by agility and specialization.

Growth partnerships Propose collaborations around co-development, clinical trial enrichment, and data-sharing opportunities with external biotech firms, leveraging their focused portfolio and growing capabilities to attract customers looking for targeted genomic solutions.